From the Journals

Diabetes, cholesterol meds use drops after bariatric surgery


 

FROM JAMA SURGERY

Causes?

As for the cause of the lack of any decline in use of cardiovascular medications versus other medications in the surgery patients, the authors speculate that the effect “may be related to aging and regain of weight over time after bariatric surgery, a phenomenon caused by hormonal, dietary, physical, and behavioral factors.”

“In contrast, as expected, a gradual increase in the use of all three medication groups was observed over time among the patients treated with no surgery for obesity,” they note.

The lower medication use with bariatric surgery can also translate to economic benefits, the authors add.

“Economically, the long-lasting reductions in medication use for hyperlipidemia, cardiovascular morbidity, and diabetes suggest that surgical treatment of morbid obesity may infer savings in medication expenses for patients, health care, and society,” they report.

“Future research may focus on subgroups that are most likely to benefit from bariatric surgery, including resolution and severity of comorbidities,” they continue.

In their editorial, Dr. Salminen and colleagues note that previous research has shown remission of dyslipidemia in up to 70% of patients after bariatric surgery that was independent of weight loss, which appears to support the sustained reduction in lipid-lowering medications following surgery observed in the current study, suggesting some benefits on lipids beyond weight loss.

Other limitations, however, include that the bariatric surgery group in the study was older and had more comorbidities than those in previous bariatric surgery studies.

“Future studies should assess this in a younger cohort with less disease at baseline and differentiation within cardiovascular disease regarding at least hypertension, ischemic heart disease, and heart failure,” the authors conclude.

The authors have reported no relevant financial relationships. Dr. Salminen has reported receiving grants from the Sigrid Jusélius Foundation, Academy of Finland, Government Research Grant Foundation, and the University of Turku (Finland).

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

What happens when newer weight loss meds are stopped?
MDedge Cardiology
New antiobesity drugs will benefit many. Is that bad?
MDedge Cardiology
Use age, not weight, to screen for diabetes; assess over 35s
MDedge Cardiology
BMI is a flawed measure of obesity. What are alternatives?
MDedge Cardiology
Tirzepatide scores win in second obesity trial, SURMOUNT-2
MDedge Cardiology
Medications provide best risk-to-benefit ratio for weight loss, says expert
MDedge Cardiology
10 popular diets for heart health ranked
MDedge Cardiology
Expert discusses which diets are best, based on the evidence
MDedge Cardiology
Boys may carry the weight, or overweight, of adults’ infertility
MDedge Cardiology
Half of teens drop below obesity cutoff with semaglutide
MDedge Cardiology